In vitro activity of sulbactam in combination with various beta-lactam antibiotics
- PMID: 2591176
- DOI: 10.1016/0732-8893(89)90130-2
In vitro activity of sulbactam in combination with various beta-lactam antibiotics
Abstract
Forty-three strains (beta-lactamase positive and negative) from the species of Haemophilus influenzae, Neisseria gonorrhoeae, Staphylococcus aureus, Escherichia coli, Serratia marcescens, Enterobacter cloacae, Acinetobacter baumanii, and Pseudomonas aeruginosa were studied for synergy between sulbactam and several beta-lactam antibiotics. Using a checkerboard method, synergy was observed with 10 to 55% of the beta-lactamase negative strains. Synergy was more frequent with the strains producing beta-lactamase. Using the killing curve method, synergy was also observed between sulbactam and beta-lactam antibiotics against some beta-lactamase negative strains. In addition, the regrowth of a resistant subpopulation was prevented by sulbactam.
Similar articles
-
In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.Arzneimittelforschung. 1990 Oct;40(10):1145-55. Arzneimittelforschung. 1990. PMID: 2291754
-
Beta-lactamase inhibitors from laboratory to clinic.Clin Microbiol Rev. 1988 Jan;1(1):109-23. doi: 10.1128/CMR.1.1.109. Clin Microbiol Rev. 1988. PMID: 3060240 Free PMC article. Review.
-
[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006].Jpn J Antibiot. 2007 Dec;60(6):344-77. Jpn J Antibiot. 2007. PMID: 18447206 Japanese.
-
Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.Am J Health Syst Pharm. 1995 Mar 15;52(6 Suppl 2):S15-22. doi: 10.1093/ajhp/52.6_Suppl_2.S15. Am J Health Syst Pharm. 1995. PMID: 7606585 Review.
-
Sulbactam-containing beta-lactamase inhibitor combinations.Clin Microbiol Infect. 2008 Jan;14 Suppl 1:185-8. doi: 10.1111/j.1469-0691.2007.01847.x. Clin Microbiol Infect. 2008. PMID: 18154545 Review.
Cited by
-
Antimicrobial prophylaxis for major head and neck surgery in cancer patients: sulbactam-ampicillin versus clindamycin-amikacin.Antimicrob Agents Chemother. 1992 Sep;36(9):2014-9. doi: 10.1128/AAC.36.9.2014. Antimicrob Agents Chemother. 1992. PMID: 1416895 Free PMC article. Clinical Trial.
-
In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone.Infection. 1991 Jan-Feb;19(1):49-53. doi: 10.1007/BF01643761. Infection. 1991. PMID: 2013510
-
Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.Eur J Clin Microbiol Infect Dis. 1993 Mar;12(3):200-5. doi: 10.1007/BF01967112. Eur J Clin Microbiol Infect Dis. 1993. PMID: 8389705
-
Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice.Antimicrob Agents Chemother. 1993 Sep;37(9):1927-30. doi: 10.1128/AAC.37.9.1927. Antimicrob Agents Chemother. 1993. PMID: 8239607 Free PMC article.
-
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.Eur J Clin Microbiol Infect Dis. 1992 Aug;11(8):728-32. doi: 10.1007/BF01989979. Eur J Clin Microbiol Infect Dis. 1992. PMID: 1330566
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
